Arsthinol (INN) is an antiprotozoal agent. It was synthesized for the first time in 1949 by Ernst A.H. Friedheim by complexation of acetarsol with 2,3-dimercaptopropanol (British anti-Lewisite) and has been demonstrated to be effective against amoebiasis and yaws. It was marketed few years latter by Endo Products (Balarsen, Tablets, 0.1 g). Among trivalent organoarsenicals, arthinol was considered as very well tolerated. Recently, it was studied for its anticancer activity.
^Cristau B, Chabas ME, Placidi M. (1975) Voies et cinétiques d'excrétion de l'arsenic chez le Cobaye après injection de divers médicaments organo-arséniés. Ann Pharm Fr 33: 577-89
^Friedheim EAH. (1949) A Five Day Peroral Treatment of Yaws with STB, a New Trivalent Arsenical. Am J Trop Med Hyg s1-29: 185
^Anonyme. (1953) New and nonofficial remedies; arsthinol. J Am Med Assoc 152: 531
^Brown CH, Gebhart WF, Reich A. (1956) Intestinal amebiasis: incidence, symptoms, and treatment with arsthinol (Balarsen). JAMA 160: 360-363
^Gibaud S, Alfonsi R, Mutzenhardt P et al. (2006) (2-Phenyl-[1, 3, 2] dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity. J Organomet Chem 691: 1081-1084
^Becherirat, S., Lanhers, M.-C., Socha, M., Yemloul, M., Astier, A., Loboda, C., Aniceto N., Gibaud S. (2013) The antitumor effects of an arsthinol-cyclodextrin complex in an heterotopic mouse model of glioma. Eur J Pharm Biopharm, doi: http://dx.doi.org/10.1016/j.ejpb.2013.06.021